The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Lei ZhangYidong LiQianchao WangZhuo ChenXiaoyun LiZhuoxun WuChaohua HuDan LiaoWei ZhangZhe-Sheng ChenPublished in: Molecular cancer (2020)
The reversal of the dual functions of ABC-transporter-mediated and AKT-activation-enhanced MDR through the inhibition or knockout of PI3K 110α or 110β promises to improve current strategies based on combined drug treatments to overcome MDR challenges.